Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Semler Scientific Reports First Quarter 2023 Financial Results

      Semler Scientific, Inc. (PRNewsfoto/Semler Scientific, Inc.)

      News provided by

      Semler Scientific, Inc.

      May 10, 2023, 16:01 ET

      Share this article

      Share this article


      2023 Q1 highlights:

      • Revenue was $18.2 million, an increase of 30% compared to the corresponding period of 2022
      • Net income was $5.0 million, an increase of 48% compared to the corresponding period of 2022
      • Cash, cash equivalents and short-term investments of $43.0 million

      SANTA CLARA, Calif., May 10, 2023 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a company that develops, manufactures and markets innovative medical products and services that assist in evaluating and treating chronic diseases, today reported financial results for the three months ended March 31, 2023.

      "We are pleased to report record quarterly revenues and pre-tax net income predominately from sales of QuantaFlo for peripheral artery disease testing," said Doug Murphy-Chutorian, MD, interim chief executive officer of Semler Scientific. "We are encouraged by our first quarter results and are highly focused on developing our business in two new disease areas, heart dysfunction and diabetes."

      FINANCIAL RESULTS

      For the first quarter ended March 31, 2023, compared to the corresponding period of 2022, Semler Scientific reported:

      • Revenue of $18.2 million, an increase of $4.2 million, or 30%, compared to $14.0 million.
        • Fixed fee software license revenues were $9.3 million, an increase of $1.4 million, or 18%, compared to $7.9 million.
        • Variable fee software license revenues were $8.6 million, an increase of $2.8 million, or 46%, compared to $5.8 million.
        • Sales of other products were $0.3 million, with no change from the prior period.
      • Cost of revenues of $1.3 million, an increase of $0.3 million, or 31%, compared to $1.0 million. As a percentage of revenues, cost of revenues was unchanged at 7%.
      • Total operating expenses of $12.0 million, which includes cost of revenues, an increase of $1.9 million, or 18%, compared to $10.1 million. As a percentage of revenues, operating expenses decreased to 65% compared to 72%.
      • Pre-tax net income of $6.6 million, an increase of $2.7 million, or 68%, compared to $3.9 million.
      • Income tax expense of $1.7 million, or an effective tax rate of 25%, compared to $0.6 million, or an effective tax rate of 15%.
      • Net income of $5.0 million, or $0.74 per basic share and $0.63 per diluted share, an increase of $1.6 million, or 48%, compared to $3.4 million, or $0.50 per basic share and $0.41 per diluted share.

      Semler Scientific's two largest customers (including their affiliates) comprised 40.9% and 33.5% of first quarter revenues in 2023.

      OTHER SIGNIFICANT EVENT

      In late March 2023, the Centers for Medicare & Medicaid Services (CMS) issued the final 2024 rate announcement with payment changes for the Medicare Advantage and Part D prescription drug programs. Essentially, CMS is phasing in a new Medicare Advantage risk adjustment model (2024 model) from the previous model (2020 model) over a three-year period. The 2024 model does not include risk adjusted payments for peripheral arterial disease (PAD) without complications, which payments many health insurers relied upon for their Medicare Advantage patients in the 2020 model. The changes will be phased in as follows: in calendar year 2023, full payment under the 2020 model; in calendar year 2024, 67% of the 2020 model; in calendar year 2025, 33% of the 2020 model. 

      Notice of Conference Call

      Semler Scientific will host a conference call today at 4:30 p.m. ET. The call will address results of the first quarter ended March 31, 2023, as well as provide a business update on Semler Scientific's market outlook and strategies for the near-term future.

      Participants are encouraged to pre-register for the conference call using the following link: https://dpregister.com/sreg/10177436/f8f3c160f0. Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time. Those without internet access or who are unable to pre-register may dial in by calling:

      Domestic callers: (866) 777–2509
      International callers: (412) 317–5413

      Please specify to the operator that you would like to join the "Semler Scientific Call." The conference call will be archived on Semler Scientific's website at www.semlerscientific.com.

      Semler Scientific, Inc.

      Statements of Income

      Unaudited

      (In thousands of U.S. Dollars, except for share and per share data)




      For the three months ended March 31, 




      2023


      2022










      Revenues


      $

      18,206


      $

      14,016


      Operating expenses:








         Cost of revenues



      1,269



      970


         Engineering and product development



      1,630



      1,126


         Sales and marketing



      5,192



      4,676


         General and administrative



      3,859



      3,302


            Total operating expenses



      11,950



      10,074


      Income from operations



      6,256



      3,942


         Interest income



      484



      1


         Change in fair value of notes held for investment



      (107)



      —


            Other income, net



      377



      1


      Pre-tax net income



      6,633



      3,943


      Income tax provision



      1,664



      583


      Net income


      $

      4,969


      $

      3,360


      Net income per share, basic


      $

      0.74


      $

      0.50


      Weighted average number of shares used in computing basic income
      per share



      6,701,199



      6,777,950


      Net income per share, diluted


      $

      0.63


      $

      0.41


      Weighted average number of shares used in computing diluted income
      per share



      7,896,043



      8,116,456


      Semler Scientific, Inc.

      Balance Sheets

      Unaudited

      (In thousands of U.S. Dollars)




      March 31, 


      December 31, 



      2023


      2022








      Assets







      Current Assets:







         Cash and cash equivalents


      $

      5,305


      $

      23,014

         Short-term investments



      37,663



      20,073

         Trade accounts receivable, net of allowance for doubtful accounts of $154 and $109,
         respectively



      9,343



      3,884

         Inventory, net



      512



      469

         Prepaid expenses and other current assets



      2,769



      1,468

         Total current assets



      55,592



      48,908

      Assets for lease, net



      2,873



      2,478

      Property and equipment, net



      703



      667

      Long-term investments



      821



      821

      Notes held for investment (includes measured at fair value of $4,072 and $3,679,
      respectively)



      5,072



      4,679

      Other non-current assets



      2,818



      2,842

      Long-term deferred tax assets



      2,378



      2,298

         Total assets


      $

      70,257


      $

      62,693








      Liabilities and Stockholders' Equity







       Current liabilities:







         Accounts payable


      $

      298


      $

      835

         Accrued expenses



      7,206



      4,748

         Deferred revenue



      1,286



      1,160

         Other short-term liabilities



      128



      114

         Total current liabilities



      8,918



      6,857








      Long-term liabilities:







      Other long-term liabilities



      138



      160

      Total long-term liabilities



      138



      160

      Commitments and contingencies







      Stockholders' equity:







         Common stock, $0.001 par value; 50,000,000 shares authorized; 6,920,643, and 
         6,906,544 shares issued, and 6,706,221 and 6,692,122 shares outstanding (treasury
         shares of 214,422 and 214,422), respectively



      7



      7

         Additional paid-in capital



      17,005



      16,449

         Retained earnings



      44,189



      39,220








         Total stockholders' equity



      61,201



      55,676








         Total liabilities and stockholders' equity


      $

      70,257


      $

      62,693

      Semler Scientific, Inc.

      Statements of Cash Flows

      Unaudited

      (In thousands of U.S. Dollars)




      Three months ended March 31,



      2023


      2022

      CASH FLOWS FROM OPERATING ACTIVITIES:







      Net income


      $

      4,969


      $

      3,360








      Reconciliation of Net Income to Net Cash Provided by Operating Activities:







         Depreciation



      129



      155

         Deferred tax (income) expense



      (80)



      179

         Loss on disposal of assets for lease



      78



      74

         Allowance for doubtful accounts



      48



      21

         Change in fair value of notes held for investment



      107



      —

         Gain on short-term investments



      (305)



      —

         Stock-based compensation



      702



      628

      Changes in Operating Assets and Liabilities:







         Trade accounts receivable



      (5,507)



      (1,818)

         Inventory



      (43)



      (45)

         Prepaid expenses and other current assets



      (1,301)



      (1,988)

         Other non-current assets



      25



      19

         Accounts payable



      (537)



      (68)

         Accrued expenses



      2,458



      946

         Other current and non-current liabilities



      118



      39

         Net Cash Provided by Operating Activities



      861



      1,502








       CASH FLOWS FROM INVESTING ACTIVITIES:







         Additions to property and equipment



      (95)



      (122)

         Proceeds from maturities of short-term investments



      20,211



      —

         Purchase of short-term investments



      (37,496)



      —

         Purchase of notes held for investment



      (500)



      —

         Purchase of assets for lease



      (544)



      (134)

         Net Cash Used in Investing Activities



      (18,424)



      (256)








      CASH FLOWS FROM FINANCING ACTIVITIES:







         Taxes paid related to net settlement of equity awards



      (146)



      (106)

         Treasury stock acquired



      —



      (99)

         Proceeds from exercise of stock options



      —



      62

         Net Cash Used in Financing Activities



      (146)



      (143)

      (DECREASE) INCREASE IN CASH



      (17,709)



      1,103

      CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD



      23,014



      37,323

      CASH AND CASH EQUIVALENTS, END OF PERIOD


      $

      5,305


      $

      38,426

      About Semler Scientific, Inc.:

      Semler Scientific, Inc. develops, manufactures and markets innovative products and services that assist in evaluating and treating chronic diseases. Its flagship product, QuantaFlo®, which is patented and cleared by the U.S. Food and Drug Administration (FDA), is a rapid point-of-care test that measures arterial blood flow in the extremities. The QuantaFlo® test aids in the diagnosis of cardiovascular diseases, such as peripheral arterial disease (PAD) and heart dysfunction (HD). QuantaFlo® is used by healthcare providers to evaluate their patient's risk of mortality and major adverse cardiovascular events (MACE). In addition, Semler Scientific has an agreement with Mellitus Health, Inc. (Mellitus) to exclusively market and distribute Insulin Insights™, an FDA cleared software product that recommends optimal insulin dosing for diabetic patients in the United States, including Puerto Rico. Semler Scientific has a minority investment in Mellitus, as well as Monarch Medical Technologies LLC, a privately held company whose product EndoTool® offers a technological solution for inpatient glycemic management. Additional information about Semler Scientific can be found at www.semlerscientific.com.

      Forward-Looking Statements

      This press release contains "forward-looking" statements. Such statements can be identified by, among other things, the use of forward-looking language such as the words "believe," "goal," "may," "will," "intend," "expect," "anticipate," "estimate," "project," "would," "could" or words with similar meaning or the negatives of these terms or by the discussion of strategy or intentions. The forward-looking statements in this release include express or implied statements regarding developing business in heart dysfunction and diabetes; continued testing of asymptomatic patients; and the benefits of early identification of at-risk patients; among others. Such forward-looking statements are subject to a number of risks and uncertainties that could cause Semler Scientific's actual results to differ materially from those discussed here, such as whether or not insurance plans and other customers will continue to license its cardiovascular testing products, including the risk of changes in the reimbursement landscape for its customers including related to the recent CMS rate announcement; whether or not it will be able to successfully expand its product offering, including into heart dysfunction and diabetes; whether or not QuantaFlo® can successfully aid in the diagnosis of heart dysfunction; along with those risk factors detailed in Semler Scientific's filings with the Securities and Exchange Commission. These forward-looking statements involve assumptions, estimates, and uncertainties that reflect current internal projections, expectations or beliefs. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. All forward-looking statements contained in this press release are qualified in their entirety by these cautionary statements and the risk factors described above. Furthermore, all such statements are made as of the date of this release and Semler Scientific assumes no obligation to update or revise these statements unless otherwise required by law.

      INVESTOR CONTACT:

      Susan A. Noonan
      S.A. Noonan Communications
      [email protected]
      917 513 5303

      SOURCE Semler Scientific, Inc.

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.